Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of OXE-103 for treatment of concussion

Trial Profile

Phase II study of OXE-103 for treatment of concussion

Phase of Trial: Phase II

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs OXE 103 (Primary)
  • Indications Concussion
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Aug 2017 There could be multiple trials in consussion and other neurological indications. I have created one please update when more information is available.
    • 07 Aug 2017 New trial record
    • 02 Aug 2017 According to an Oxeia Biopharmaceuticals media release, the company anticipates initiation of this study in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top